Tirzepatide Dosage Chart: Titration Schedule by Week (2026)

Medically reviewed by clinical staff at OC Weight Loss and Medspa. Last updated May 2026.

In one paragraph. Tirzepatide is started at 2.5 mg once weekly and increased by 2.5 mg every four weeks to a maximum of 15 mg. The full ladder is 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, with 20 weeks between start and top dose if you climb every step. Maintenance can sit at any dose between 5 mg and 15 mg, depending on how the weight loss is going and how the gut is tolerating the medication. Slower climbs are common; faster climbs are not allowed by the FDA label.

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) is FDA-approved with a fixed titration schedule. The schedule is conservative on purpose: it gives the gut and brainstem time to adapt to the dual GLP-1 and GIP receptor effects that make the drug work. This chart shows the dose ladder, the rationale at each step, and the decision points where holding or pausing is the right call. For the full GLP-1 conversation, see our GLP-1 weight loss guide.

The standard tirzepatide dosage chart

This is the ladder, exactly as it appears in the FDA label for tirzepatide (FDA tirzepatide prescribing information). Each step is four weeks at minimum; longer holds are allowed at any dose.

Why the schedule is so slow

Tirzepatide is a dual incretin agonist — it activates both GLP-1 and GIP receptors. Both pathways slow gastric emptying, dampen appetite, and shift how the body handles glucose and lipids. The body’s response to that signaling has a built-in adaptation period: the gut needs roughly 14 days to recalibrate motility, and the brainstem needs roughly 21-28 days to recalibrate satiety set-points. Pushing the dose faster than that produces the same outcomes (intolerable nausea, vomiting, dropouts) seen in the early phase-1 studies that tested faster titration.

In SURMOUNT-1, the trial that established tirzepatide for obesity, escalation to maximum dose was complete by week 20 and weight loss continued to deepen through week 72 — average 20.9% loss at the 15 mg dose (SURMOUNT-1, NEJM 2022). There is no clinical reason to compress the schedule; the long tail of weight loss happens at steady dose, not during the climb.

When to escalate to the next dose

Standard escalation criteria we use at the four-week check-in:

• Nausea is mild and limited to the 24-48 hours after injection
• Fluid intake is at least 80 oz per day with no signs of dehydration
• Resting heart rate is stable or up no more than 4 bpm
• No new severe abdominal pain, no jaundice, no thyroid lump
• Patient feels ready (this matters)

When to hold the current dose

Holding is not failing. Many of our long-term maintenance patients sit at 7.5 mg or 10 mg forever. Reasons to hold:

• Weight loss is on track (0.75-1.5 lb per week) — no need to escalate
• Mild but persistent nausea or constipation at the current dose
• You are at or close to goal weight
• You have hit a comfortable maintenance pattern
• The next dose increase would push protein intake below 0.7 g per lb of goal weight

When to slow the schedule (six- to eight-week steps)

About one in five of our patients does better on a slower schedule — six to eight weeks at each dose rather than four. Reasons we slow it down:

• Nausea has not resolved by the end of week 3 of the current step
• The patient has had to skip a dose because of side effects
• Bioimpedance shows muscle loss outpacing fat loss
• Hair shedding starts before goal weight is reached (often a signal of too-fast weight loss or low protein)
• A history of GI sensitivity (IBS, GERD, post-cholecystectomy)

For a full read on the side-effect drivers behind these decisions, see our deep dive into tirzepatide side effects.

When to pause or stop

Hard stops, not “wait it out”:

• Severe abdominal pain radiating to the back — pancreatitis evaluation
• Right-upper-quadrant pain with fatty meals — gallstones
• Vomiting that prevents fluid intake for 24+ hours
• Pregnancy or active pregnancy attempt
• Planned upper endoscopy or general anesthesia (most anesthesiologists want tirzepatide held for at least seven days because of delayed gastric emptying)

Tirzepatide vs. Zepbound dosing — same molecule, same ladder

Zepbound and Mounjaro are the same drug (tirzepatide) made by the same manufacturer. Zepbound is the brand approved for weight management; Mounjaro is the brand approved for type 2 diabetes. The titration schedule is identical. The dosing pens are interchangeable in concept — a 5 mg Zepbound pen and a 5 mg Mounjaro pen deliver the same dose.

Compounded tirzepatide, where available, uses the same dosing structure. Practitioners working with compounded versions should follow the FDA’s labeled titration, not invent faster schedules.

Missed-dose protocol

• Less than 4 days late: take the missed dose as soon as you remember, then resume the normal weekly schedule on the original day.
• More than 4 days late: skip the missed dose and take the next one on the regular day.
• Two consecutive missed doses (gap of 2-3 weeks): usually safe to restart at the same dose, but expect a brief return of week-1-style nausea.
• Three or more missed doses (gap of 3+ weeks): re-titrate. Restart at the previous step or at 2.5 mg if it has been more than a month, then climb again.

Choosing a maintenance dose

There is no universal “best” maintenance dose. The cleanest decision framework:

• Lowest dose at which weight is stable at goal
• Lowest dose at which appetite is well-controlled without daily side effects
• Lowest dose the patient can stay on financially

In our practice, maintenance doses cluster at 5 mg, 7.5 mg, and 10 mg. About 20% of patients need 12.5 mg or 15 mg long-term. For a closer look at expected progress, see how long does tirzepatide take to work.

Common mistakes with the dosage chart

• Skipping the 2.5 mg starter. Some providers jump in at 5 mg “to save four weeks.” The trade-off is much worse early nausea and a higher dropout rate. Not worth it.
• Climbing through plateaus. A two- to three-week pause in scale movement is normal at any dose. Escalating to chase it is a poor decision.
• Treating side effects with more dose. Hair loss, fatigue, and muscle loss are signals to slow down, not push harder.
• Stopping cold turkey at goal weight. Real-world data and the SURMOUNT-4 withdrawal trial both show rapid weight regain after discontinuation. Plan a taper or a long maintenance phase, not an abrupt stop.

Frequently asked questions

Talk to a clinician at OC Weight Loss and Medspa

Dose decisions look simple on a chart and feel more nuanced in practice. Our team runs the four-week check-ins in person, watches for muscle loss and shedding, and adjusts the schedule when the chart says one thing and your body says another. Learn more about tirzepatide for weight loss.

Book a free consultation